Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
85.36
+0.52 (0.61%)
Feb 18, 2026, 11:02 AM EST - Market open
Kymera Therapeutics Employees
Kymera Therapeutics had 225 employees as of September 30, 2025. The number of employees increased by 41 or 22.28% compared to the same quarter last year.
Employees
225
Change
41
Growth
22.28%
Revenue / Employee
$194,378
Profits / Employee
-$1,311,653
Market Cap
6.83B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 225 | 41 | 22.28% |
| Jun 30, 2025 | 218 | 37 | 20.44% |
| Mar 31, 2025 | 208 | 22 | 11.83% |
| Dec 31, 2024 | 188 | 1 | 0.53% |
| Sep 30, 2024 | 184 | -8 | -4.17% |
| Jun 30, 2024 | 181 | 0 | - |
| Mar 31, 2024 | 186 | 12 | 6.90% |
| Dec 31, 2023 | 187 | 20 | 11.98% |
| Sep 30, 2023 | 192 | 23 | 13.61% |
| Jun 30, 2023 | 181 | 21 | 13.13% |
| Mar 31, 2023 | 174 | 31 | 21.68% |
| Dec 31, 2022 | 167 | 26 | 18.44% |
| Sep 30, 2022 | 169 | 33 | 24.26% |
| Jun 30, 2022 | 160 | 48 | 42.86% |
| Mar 31, 2022 | 143 | 51 | 55.43% |
| Dec 31, 2021 | 141 | 66 | 88.00% |
| Sep 30, 2021 | 136 | 72 | 112.50% |
| Jun 30, 2021 | 112 | 57 | 103.64% |
| Mar 31, 2021 | 92 | 37 | 67.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,769 |
| PTC Therapeutics | 939 |
| ImmunityBio | 673 |
| Cytokinetics | 498 |
| Vaxcyte | 414 |
| Mirum Pharmaceuticals | 355 |
| Rhythm Pharmaceuticals | 283 |
| Krystal Biotech | 275 |
KYMR News
- 5 weeks ago - Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs - GlobeNewsWire
- 2 months ago - Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 2 months ago - Kymera Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 2 months ago - This Drugmaker's Stock Is Soaring Over 40% Monday - Investopedia
- 2 months ago - Kymera Therapeutics, Inc. (KYMR) Discusses KT-621 BroADen Phase 1b Results in Atopic Dermatitis Transcript - Seeking Alpha
- 2 months ago - Kymera's KT-621 Shines: Phase 1b Data Boosts Momentum - Seeking Alpha
- 2 months ago - Kymera Therapeutics Stock Soars 30%. Why Investors Are Excited About Its Anti-Inflammatory Drug. - Barrons